BioCardia (BioCardia) EBIT per Share : $-7.09 (TTM As of Mar. 2024)

View and export this data going back to 1996. Start your Free Trial

What is BioCardia EBIT per Share?

BioCardia's EBIT per Share for the three months ended in Mar. 2024 was $-1.36. Its EBIT per Share for the trailing twelve months (TTM) ended in Mar. 2024 was $-7.09.

During the past 3 years, the average EBIT per Share Growth Rate was 29.00% per year. During the past 5 years, the average EBIT per Share Growth Rate was 32.30% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EBIT per Share growth rate using EBIT per Share data.

The historical rank and industry rank for BioCardia's EBIT per Share or its related term are showing as below:

BCDA' s 3-Year EBIT Growth Rate Range Over the Past 10 Years
Min: 8.7 Med: 35.6 Max: 64.1
Current: 29

During the past 13 years, the highest 3-Year average EBIT per Share Growth Rate of BioCardia was 64.10% per year. The lowest was 8.70% per year. And the median was 35.60% per year.

BCDA's 3-Year EBIT Growth Rate is ranked better than
80.23% of 1305 companies
in the Biotechnology industry
Industry Median: 3.5 vs BCDA: 29.00

BioCardia's EBIT for the three months ended in Mar. 2024 was $-2.28 Mil.

BioCardia EBIT per Share Historical Data

The historical data trend for BioCardia's EBIT per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

BioCardia EBIT per Share Chart

BioCardia Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

EBIT per Share

Get a 7-Day Free Trial

-38.82

-22.22

-11.20

-10.08

-8.25

BioCardia Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
EBIT per Share	Get a 7-Day Free Trial															-2.61	-2.54	-1.80	-1.39	-1.36

BioCardia EBIT per Share Calculation

EBIT per Share is the amount of Earnings Before Interest and Taxes (EBIT) per outstanding share of the company's stock.

Earnings Before Interest and Taxes (EBIT) is what the company earns before it expenses interest and taxes.

BioCardia's EBIT per Share for the fiscal year that ended in Dec. 2023 is calculated as

	EBIT per Share		(A: Dec. 2023 )
=	EBIT	/	Shares Outstanding (Diluted Average)
=	-11.644	/	1.412
=	-8.25

BioCardia's EBIT per Share for the quarter that ended in Mar. 2024 is calculated as

	EBIT per Share		(Q: Mar. 2024 )
=	EBIT	/	Shares Outstanding (Diluted Average)
=	-2.275	/	1.676
=	-1.36

EBIT per Share for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-7.09

BioCardia (NAS:BCDA) EBIT per Share Explanation

EBIT is a company's earnings before interest and tax expenses are deducted. It measures a company's profit generates from operating, ignoring tax burden and capital structure. As the tax expense are not deducted, EBIT is helpful when comparing companies in the same industry but with different tax situations. Also, the interest expense are included in EBIT, making it useful to compare companies that have high interest expenses due to large amount of debt.

BioCardia EBIT per Share Related Terms

Thank you for viewing the detailed overview of BioCardia's EBIT per Share provided by GuruFocus.com. Please click on the following links to see related term pages.

BioCardia (BioCardia) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » BioCardia Inc (NAS:BCDA) » Definitions » EBIT per Share

Comparable Companies

Traded in Other Exchanges

6JU:Germany

Address

320 Soquel Way, Sunnyvale, CA, USA, 94085

Website

https://www.biocardia.com

BioCardia Inc is a clinical stage regenerative medicine company. It is developing therapeutics for cardiovascular and pulmonary diseases with large unmet medical needs. The company is developing comprehensive biotherapeutic candidates for cardiac regenerative medicine namely CardiAMP and CardiALLO, with a focus on heart failure resulting from a heart attack.

Executives

Frost Phillip Md Et Al	10 percent owner	4400 BISCAYNE BLVD, MIAMI FL 33137-3227
Bill Facteau	director	C/O BIOCARDIA, INC., 320 SOQUEL WAY, SUNNYVALE CA 94085
Frost Gamma Investments Trust	10 percent owner	4400 BISCAYNE BLVD, MIAMI FL 33137
Krisztina M Zsebo	director	C/O CELLADON CORPORATION, 12760 HIGH BLUFF DRIVE, SUITE 240, SAN DIEGO CA 92130
Edward M Gillis	officer: Senior Vice President, Devices	C/O BIOCARDIA, INC., 125 SHOREWAY ROAD, SUITE B, SAN CARLOS CA 94070
Andrew Scott Blank	director	C/O BIOCARDIA, INC., 125 SHOREWAY ROAD, SUITE B, SAN CARLOS CA 94070
Jim L. Allen	director	C/O BIOCARDIA, INC., 125 SHOREWAY ROAD, SUITE B, SAN CARLOS CA 94070
Simon H Stertzer	director	C/O BIOCARDIA, INC., 125 SHOREWAY DRIVE, SUITE B, SAN CARLOS CA 94070
Peter Altman	director, officer: President and CEO	C/O BIOCARDIA INC, 125 SHOREWAY ROAD SUITE B, SAN CARLOS CA 94070
Stertzer Family Trust	10 percent owner	C/O BIOCARDIA INC, 125 SHOREWAY ROAD SUITE B, SAN CARLOS CA 94070
Kimberly Stertzer	10 percent owner	C/O BIOCARDIA INC, 125 SHOREWAY ROAD SUITE B, SAN CARLOS CA 94070
David Mcclung	officer: VP of Finance	C/O BIOCARDIA, INC., 125 SHOREWAY ROAD, SUITE B, SAN CARLOS CA 94070
Allan R Tessler	director	C/O EPOCH HOLDING CORPORATION, 640 FIFTH AVENUE, NEW YORK, NY 10019
Richard T Allen	officer: VP, Quality Assurance	C/O BIOCARDIA, INC., 125 SHOREWAY ROAD, SUITE B, SAN CARLOS CA 94070
Thomas Quertermous	director	C/O BIOCARDIA INC, 125 SHOREWAY ROAD SUITE B, SAN CARLOS CA 94070